Bone Biologics raises $3M to extend runway through Q2 2027
Bone Biologics Corp secured approximately $3 million via an at-the-market private placement and intends to fund clinical development and working capital. The funding provokes strategic runway and execution plans for its NB1 spinal fusion therapy through Q2 2027.
View filing at SEC.gov →